XNAS · Healthcare · Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Q1 2026 | 4.18 | 4.47 | +6.94% | $2.99B | ✅ Beat | -1.10% | +1.24% | -0.35% |
| 2026-02-12 | Q4 2025 | 4.85 | 5.03 | +3.71% | $3.19B | ✅ Beat | -1.24% | +0.91% | +0.93% |
| 2025-11-03 |
| Q3 2025 |
| 4.35 |
| 4.80 |
| +10.34% |
| $3.08B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-04 | Q2 2025 | 4.05 | 4.52 | +11.88% | $2.96B | ✅ Beat | — | — | — |
| 2025-05-05 | Q1 2025 | 4.29 | 4.06 | -5.36% | $2.77B | ❌ Miss | — | — | — |
| 2025-02-10 | Q4 2024 | 4.02 | 3.98 | -1.00% | $2.91B | ❌ Miss | — | — | — |
| 2024-11-04 | Q3 2024 | 4.14 | 4.38 | +5.80% | $2.77B | ✅ Beat | — | — | — |
| 2024-08-01 | Q2 2024 | 4.14 | -12.83 | -409.90% | $2.65B | ❌ Miss | — | — | — |
Showing last 8 quarters.